The ₹166.80 crore Xtranet Technologies IPO opened for subscription today, July 23, 2026, with a price band of ₹120 to ₹127 per share. As of 10:30 AM on Day 1, the issue had been subscribed 0.16 times.
The IPO will remain open for subscription until July 27, 2026. The basis of allotment is expected to be finalised on July 28, 2026, while the shares are tentatively scheduled to be listed on the NSE and BSE on July 30, 2026.
The expected IPO schedule is as follows:
|
Event |
Date |
|
Subscription Opening Date |
23 July 2026 |
|
Subscription Closing Date |
27 July 2026 |
|
Basis of Allotment Date |
28 July 2026 |
|
Refund Initiation Date |
29 July 2026 |
|
Credit of Shares |
29 July 2026 |
|
Listing on BSE and NSE |
30 July 2026 |
Note: The allotment and listing dates are tentative and may be revised.
The company proposes to utilise the net proceeds from the fresh issue for the following purposes:
Explore other Upcoming IPOs on BSE and NSE.
[July 23, 2026, 10:30 AM]
|
Category |
Subscription (x) |
|
Qualified Institutional Buyers (QIBs) |
0.00x |
|
Non-Institutional Investors (NIIs) |
0.08x |
|
Retail Individual Investors (RIIs) |
0.29x |
|
Total |
0.16x |
Incorporated in 2002, Xtranet Technologies Limited provides integrated IT solutions across enterprise applications, digital transformation, managed services, system integration, and secure digital solutions. Its service portfolio includes application development, ERP implementation, data centre services, business intelligence, and PKI-enabled digital signature solutions. The company caters to government, public sector undertakings (PSUs), and private sector clients across various industries through both onsite and offshore delivery models.
|
Particulars |
FY25 (in ₹ crore) |
FY24 (in ₹ crore) |
FY23 (in ₹ crore) |
|
Revenue from Operations |
276.08 |
232.94 |
225.55 |
|
Profit After Tax |
30.03 |
10.94 |
5.98 |
|
EBITDA |
47.65 |
19.18 |
13.44 |
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here